Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 537291 | NSE Symbol : NATHBIOGEN | ISIN : INE448G01010 | Industry : Miscellaneous |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
04-Jul-2025	11-Jul-2025	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2025 inter alia to consider and approve unaudited financial results as on 30th June 2025. The Board of Directors of the Company at Meeting held today on 11th July 2025 has approved the following, 1. Stanaldone and Consolidated Financial Results as on 30th June 2025. 2. Appointment of Ms. Payal Jain as Additional Director (Independent) of the Company. (As Per BSE Announcement Dated on :11.07.2025)
21-Apr-2025	29-Apr-2025	Final Dividend	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2025 inter alia to consider and approve Audited Financial Results for the quarter and financial year ended 31st March 2025 The Board on meeting held today on 29th April 2025 has approved the following. 1. Standalone Audited Financial Results as on 31st March 2025 along with Auditors Report 2. Consolidated Audited Financial Results as on 31st March 2025 along with Auditors Report 3. Other Disclosure/ Announcements. (As Per BSE Announcement dated on 29.04.2025)
15-Jan-2025	23-Jan-2025	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2025 inter alia to consider and approve unaudited financial results for the period ended 31st December 2024 Nath Bio-Genes (India) Ltd has informed BSE regarding Outcome of Board Meeting held on January 23, 2025. (As Per BSE Announcement Dated on: 23/01/2025)
17-Oct-2024	23-Oct-2024	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended 30th September 2024. Outcome of Board Meeting (As Per BSE Announcement Dated on: 23/10/2024)
30-Jul-2024	07-Aug-2024	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve Unaudited financial results as on 30th June 2024. Unaudited financial results as at 30th June 2024. (As Per BSE Announcement dated on 07.08.2024)
30-Apr-2024	08-May-2024	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2024 ,inter alia, to consider and approve Audited Financial Results for the year ended 31st March 2024. Outcome of Board meeting held on 08th May 2024 for approval of 1. Audited Financial Results as on 31st March 2024. 2. Recommendation of Dividend by Board of Directors 3. Date of Annual General Meeting of the Company for financial year 2023-24 Outcome of Board Meeting of the Company held on 08th May 2024. Outcome of Board meeting held on 08th May 2024 for approval of 1. Audited Financial Results as on 31st March 2024. 2. Recommendation of Dividend by Board of Directors 3. Date of Annual General Meeting of the Company for financial year 2023-24 (As Per BSE Announcement Dated on 08.05.2024)
09-Jan-2024	18-Jan-2024	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/01/2024 inter alia to consider and approve Unaudited Financial Results as of 31st December 2023. Outcome of Board Meeting (As Per BSE Announcement Dated on 18/01/2024)
06-Oct-2023	16-Oct-2023	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2023 inter alia to consider and approve of unaudited financial results as on 30th Sept 2023 Unaudited financial results as of 30th Sept 2023 Financial Results as on 30th Sept 2023 (As Per BSE Announcement dated on 16.10.2023)
02-Aug-2023	10-Aug-2023	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Unaudited financial results as on 30th June 2023 Financial Results as on 30th June 2023 (As per BSE Announcement Dated on 10/08/2023)
15-Apr-2023	22-Apr-2023	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/04/2023 inter alia to consider and approve audited financial results for the quarter and financial year ended 31st March 2023. Final Dividend & Audited Results (As per BSE Bulletin dated on 17/04/2023) The outcome of the Board Meeting held on 22nd April 2023. Audited Financial Results as of 31st March 2023 (As per BSE Announcement Dated on 22/04/2023)
03-Feb-2023	14-Feb-2023	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Unaudited financial results for the quarter and nine months ended 31st December 2022. Unaudited Financial Results as on 31st December 2022. (As per BSE Announcement Dated on 14/02/2023)
13-Oct-2022	20-Oct-2022	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2022 inter alia to consider and approve unaudited financial results for 30th Sept 2022. Financial Results as on 30.09.2022 Unaudited Financial Results as on 30.09.2022 (As Per BSE Announcement Dated on 20/10/2022)
08-Aug-2022	13-Aug-2022	Quarterly Results	Quarterly Results Financial Results as on 30th June 2022 (As Per BSE Announcement Dated on 13/08/2022)
24-May-2022	30-May-2022	Accounts	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Audited financial results of the Company for the financial year ended 31st March 2022. Nath Bio-Genes (India) Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended dividend for financial year 2021-22 of Rs. 2/- (i.e. 20%) per equity shares of the nominal value of Rs. 10.00 per share fully paid up, subject to approval of shareholders in upcoming Annual General Meeting of the Company. Outcome of Board Meeting held on 30th May 2022. Audited Financial Results as on 31st March 2022 (As Per BSE Announcement dated on 30.05.2022)
04-Feb-2022	11-Feb-2022	Quarterly Results	Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve financial results for the quarter and nine months ended 31st December 2021. Financial Results as on 31st December 2021. (As Per BSE Announcement dated on 11.02.2022)

1 2

LOGIN HERE

Nath Bio-Genes (India) Ltd

Board Meeting